ArticleFrontiers in bioengineering and biotechnology2025
Platelet-rich plasma-enhanced "plum blossom" bone grafting for refractory femoral nonunion: a single-center study of 33 cases.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Revision surgery for femoral nonunion is technically challenging, and there is limited evidence supporting effective treatments for cases with multiple failed revisions. This study aims to evaluate the efficacy of platelet-rich plasma-enhanced "plum blossom" bone grafting combined with a bioactive chamber in treating refractory femoral nonunion after multiple failed revisions. Methods: A retrospective analysis was conducted on patients with refractory femoral nonunion treated at a high-level trauma center between January 2021 and July 2024. These patients underwent mechanical optimization, platelet-rich plasma -enhanced "plum blossom" autologous iliac bone grafting, and bioactive chamber therapy. Radiographic outcomes included union rate and limb shortening, while clinical outcomes encompassed healing time, visual analog scale pain score, SF-36 quality of life score, Harris hip score, and complications. Results: Thirty-three patients were included (24 males, 9 females), with a mean age of 42.64 ± 13.03 years. The average number of previous surgeries was 2.64 ± 1.17. The nonunion types were hypertrophic (4 cases, 12.10%), atrophic (24 cases, 72.70%), and oligotrophic (5 cases, 15.20%). The mean bone defect was 3.87 ± 1.05 cm, and the mean follow-up duration was 16.06 ± 3.37 months. The union rate was 96.97% (32/33), with a mean healing time of 9.78 ± 1.75 months. Post-treatment, significant improvements were observed in VAS score (4.27 ± 1.18 vs. 1.21 ± 1.05, p < 0.001), Harris hip score (50.91 ± 8.47 vs. 86.39 ± 7.75, p < 0.001), SF-36 score (59.21 ± 5.63 vs. 84.48 ± 5.32, p < 0.001), and limb shortening (2.20 ± 0.64 vs. 0.32 ± 0.57, p < 0.001). Two patients (6.06%) experienced severe complications (1 case of persistent nonunion, 1 case of deep vein thrombosis). Conclusion: The synergistic effect of biomechanical stability and biological stimulation is a critical pathway to overcoming traditional treatment limitations. This study provides a reference method for managing refractory and recalcitrant femoral nonunion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.